Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine

NCT01903837 is registered in ClinicalTrials.gov with Alkermes, Inc. as lead sponsor.

NCT NCT01903837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01903837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine
Lead sponsor
Alkermes, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2013
Completion date
March 31, 2015
Enrollment
347 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia